Literature DB >> 31532579

Impact of new hypertension guidelines on target organ damage screening in a Shanghai community-dwelling population.

Qian Wang1, Huijuan Chao1, Shuping Zheng2, Isabella Tan3, Mark Butlin3, Alberto Avolio3, Junli Zuo1,3.   

Abstract

Recently, the 2017 ACC/AHA released new hypertension guidelines and proposed a redefinition of hypertension from 140/90 to 130/80 mm Hg. This study assesses the impact of the lower threshold for hypertension diagnosis on the association of hypertension with target organ damage (TOD). Health checks were conducted in a community-dwelling population in Shanghai in 2017 (N = 10 826; 43.26% mean, age 62 ± 12 years [range 29-95 years]). Subclinical TOD indices were quantified in terms of left ventricular hypertrophy (LVH) by electrocardiogram (Sokolow-Lyon standard), estimated glomerular filtration rate (eGFR), and presence of proteinuria. Information on clinical TOD was obtained by questionnaire. Arteriosclerotic cardiovascular disease (ASCVD) was determined by the 2013 ACC/ AHA recommended guidelines. Compared to the higher threshold (140/90 mm Hg), the lower threshold (130/80 mm Hg) was associated with variable rates of increased detection of hypertension and TOD: (a) Hypertension: incidence of hypertension, 29.5% (51.8%-81.5%) increase in persons with hypertension if the threshold of 130/80 mm Hg is used; (b) Subclinical TOD: LVH, 20.8%; eGFR (30-60 mL/min per 1.73 m2 ), 23.7%; proteinuria, 23.5%; (c) Clinical TOD: chronic kidney disease (CKD) IV (eGFR<30 mL/min per 1.73 m2 ), 3.1%; diabetes (fasting glucose ≥7.0 mmol/L or HbA1C>7.0%), 24.3%; stroke, 26.4%; chronic heart disease, 28.1%; acute myocardial infarction, 19.5% (69.4% to 88.9% of total of 36); ASCVD ≥10%, 29.3%. The lower threshold was associated with a significantly higher detection rate of clinical and subclinical TOD of approximately 20% compared to the higher threshold. 15%-20% of TOD and 29% of ASCVD were also found below the lower threshold of hypertension. ©2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  arteriosclerotic cardiovascular disease (ASCVD); high threshold of hypertension; low threshold of hypertension; new hypertension guidelines; target organ damage

Mesh:

Year:  2019        PMID: 31532579      PMCID: PMC8030608          DOI: 10.1111/jch.13677

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  27 in total

Review 1.  Selected major risk factors and global and regional burden of disease.

Authors:  Majid Ezzati; Alan D Lopez; Anthony Rodgers; Stephen Vander Hoorn; Christopher J L Murray
Journal:  Lancet       Date:  2002-11-02       Impact factor: 79.321

2.  Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension.

Authors:  D W Brown; W H Giles; J B Croft
Journal:  Am Heart J       Date:  2000-12       Impact factor: 4.749

3.  Presence of baseline prehypertension and risk of incident stroke: a meta-analysis.

Authors:  M Lee; J L Saver; B Chang; K-H Chang; Q Hao; B Ovbiagele
Journal:  Neurology       Date:  2011-09-28       Impact factor: 9.910

Review 4.  A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension.

Authors:  Michael H Olsen; Sonia Y Angell; Samira Asma; Pierre Boutouyrie; Dylan Burger; Julio A Chirinos; Albertino Damasceno; Christian Delles; Anne-Paule Gimenez-Roqueplo; Dagmara Hering; Patricio López-Jaramillo; Fernando Martinez; Vlado Perkovic; Ernst R Rietzschel; Giuseppe Schillaci; Aletta E Schutte; Angelo Scuteri; James E Sharman; Kristian Wachtell; Ji Guang Wang
Journal:  Lancet       Date:  2016-09-23       Impact factor: 79.321

5.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

Authors:  Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

6.  Global Impact of 2017 American Heart Association/American College of Cardiology Hypertension Guidelines: A Perspective From India.

Authors:  Gurpreet S Wander; C Venkata S Ram
Journal:  Circulation       Date:  2018-02-06       Impact factor: 29.690

Review 7.  Consensus Document on Improving Hypertension Management in Asian Patients, Taking Into Account Asian Characteristics.

Authors:  Kazuomi Kario; Chen-Huan Chen; Sungha Park; Chang-Gyu Park; Satoshi Hoshide; Hao-Min Cheng; Qi-Fang Huang; Ji-Guang Wang
Journal:  Hypertension       Date:  2018-01-08       Impact factor: 10.190

Review 8.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.

Authors:  Dena Ettehad; Connor A Emdin; Amit Kiran; Simon G Anderson; Thomas Callender; Jonathan Emberson; John Chalmers; Anthony Rodgers; Kazem Rahimi
Journal:  Lancet       Date:  2015-12-24       Impact factor: 79.321

9.  Impact of new hypertension guidelines on target organ damage screening in a Shanghai community-dwelling population.

Authors:  Qian Wang; Huijuan Chao; Shuping Zheng; Isabella Tan; Mark Butlin; Alberto Avolio; Junli Zuo
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-09-18       Impact factor: 3.738

10.  A Meta-Analysis on Prehypertension and Chronic Kidney Disease.

Authors:  Yang Li; Peng Xia; Lubin Xu; Yang Wang; Limeng Chen
Journal:  PLoS One       Date:  2016-06-01       Impact factor: 3.240

View more
  1 in total

1.  Impact of new hypertension guidelines on target organ damage screening in a Shanghai community-dwelling population.

Authors:  Qian Wang; Huijuan Chao; Shuping Zheng; Isabella Tan; Mark Butlin; Alberto Avolio; Junli Zuo
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-09-18       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.